Gan & Lee Pharmaceuticals

Baidu Online Network Technology (beijing) Co., Ltd.

Beijing Baidu Netcom Science and Technology Co., Ltd.

Lei Yin

Heng Li

Wenjian Liu

Dianxi Zhu

The embodiments disclosed herein provide compounds as shown in formula I or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, a deuterated compound, a prodrug or a mixture thereof, or a pharmaceutically acceptable salt or solvate of the compounds as shown in formula I or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, a deuterated compound, a prodrug or a mixture thereof, wherein Rto Rare as defined in the description. This application also provides a preparation method and a medical use of the compounds. The compounds of this disclosure have an activity superior or equivalent to the candidate drug LY2835219 currently under phase III clinical trial, and some of the compounds exhibit better selectivity. Moreover, the preferred compounds exhibit good absorption and good blood-brain distribution when administered orally. The compounds of this disclosure thus show promise for development into novel drugs for the treatment of diseases associated with cell proliferation, particularly brain tumors, providing new options for clinicians and patients.

Protein kinase inhibitors, preparation method and medical use thereof

The embodiments disclosed herein provide compounds as shown in formula I or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, a deuterated compound, a prodrug or a mixture thereof, or a pharmaceutically acceptable salt or solvate of the compounds as shown in formula I or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, a deuterated compound, a prodrug or a mixture thereof, wherein Rto Rare as defined in the description. This application also provides a preparation method and a medical use of the compounds. The compounds of this disclosure have an activity superior or equivalent to the candidate drug LY2835219 currently under phase III clinical trial, and some of the compounds exhibit better selectivity. Moreover, the preferred compounds exhibit good absorption and good blood-brain distribution when administered orally. The compounds of this disclosure thus show promise for development into novel drugs for the treatment of diseases associated with cell proliferation, particularly brain tumors, providing new options for clinicians and patients. 

The invention provides a compound of Formula I, or its tautomer, mesomer, racemate, enantiomer, diastereoisomer or a mixture thereof, or a pharmaceutically acceptable salt or solvate of the compound of Formula I, its tautomer, mesomer, racemate, enantiomer, or diastereoisomer. Ring A, R, R, Rand Rare as defined in the specification. The invention further provides a method for preparing the compound of Formula I and their use in the manufacture of a medicament for the treatment of a cell proliferative disorder. 

Kinase inhibitor, and preparing method and pharmaceutical use thereof

A method and a device for inquiring a map are provided. The method includes receiving a query statement inputted by a user; performing a word segmentation on the query statement received to obtain a result of the word segmentation; extracting specific information related to a demand of the user from the result of the word segmentation; inquiring a route and/or a point of interest related to the specific information extracted in a map.

Method and device for inquiring map

Provided are a location-based positioning method and system. The method comprises the following steps. A positioning request is received from a terminal and a location and a moving trajectory of the terminal are determined. A predicted trajectory is calculated according to the moving trajectory and road network information. A positioning request is received from the terminal at a position correction point, and a moving direction and a moving speed of the terminal is received in accordance with a location of the position correction point and the predicted trajectory. A next location of the terminal in the determined moving direction is determined based on the predicted trajectory.

Growing community of inventors

Beijing, China

Lei Yin